Abbott's Ablation Catheter Posts 87% Arrhythmia-Free Rate, UltiSynq Lead Hits 99% Pacing Success
Abbott's TactiFlex Duo Ablation Catheter reported an 87% arrhythmia-free rate and 98.3% safety in the 188-patient FlexPulse IDE trial, with 93.3% treated exclusively with pulsed field ablation. Early conduction system pacing data show the UltiSynq ICD lead achieved 99% left bundle pacing success, 100% defibrillation efficacy and 97.5% safety.
1. FlexPulse IDE Trial Delivers Strong Catheter Outcomes
Six-month results from the 188-patient FlexPulse IDE study for the TactiFlex™ Duo Ablation Catheter show an 87% freedom from documented arrhythmias and a 98.3% safety profile. The majority (93.3%) of patients were treated exclusively with pulsed field ablation, and 93.9% required no additional ablation.
2. Volt PFA System Extension Cohort Demonstrates Efficiency
The Volt CE Mark Extension Cohort trial reported that physicians treated the posterior wall with an average of 4.1 applications per vein and 10.7 per PWI, citing intuitive design and ease of use. No patient or procedure-related complications were observed, underscoring the system’s high safety profile.
3. ASCEND CSP IDE Trial Validates UltiSynq ICD Lead
Three-month data for the investigational UltiSynq™ CSP ICD lead show a 97.5% safety rate with no major lead-related events, a 99% left bundle branch area pacing success rate, 86% strict LBBP success and 100% defibrillation efficacy, with fewer than one repositioning attempt per patient.
4. AVEIR Leadless Pacemaker Shows Promising Early Results
In the first-in-human LEAP2 feasibility study of the AVEIR™ CSP leadless pacemaker, 19 patients achieved high implantation success with reliable electrical performance and pacing that follows natural conduction pathways, plus consistent dual-chamber device communication through one month.